364: Closing a zombie biotech, and Lilly's disappointing obesity readout
The Readout Loud
00:00
Rethinking Biotech Liquidation
This chapter explores the complexities of shutting down a biotech company, emphasizing the need to question conventional financial wisdom. By sharing personal experiences, the speakers advocate for a data-driven approach and swift decision-making in the face of non-viability.
Transcript
Play full episode
